Orgenesis – ORGS

Orgenesis Inc , a biotech company, focusing on cell and gene therapies worldwide.

infoOrgenesis is a micro cap stock with a total market cap of 29.76M.

infoThey trade on the NASDAQ and had their IPO 11 years and 5 months ago.

infoOrgenesis currently employs 167 people.

infoAs of Friday, Aug 11 2023, Orgenesis’s share price is $1.05.

newspaper
News Relating to Orgenesis
GlobeNewsWire
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call

Thursday Aug 10 2023 at 08:30

GERMANTOWN, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT), today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, August 11, 2023, to discuss the company’s corporate progress and other developments.


GlobeNewsWire
Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1×1 Investor Conference on May 23, 2023

Friday May 19 2023 at 08:30

GERMANTOWN, Md., May 19, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, today announced that Vered Caplan, CEO of Orgenesis, will be participating in the Benchmark Company’s 3rd Annual Healthcare House Call Virtual 1×1 Conference, which will be held on Tuesday, May 23, 2023.


GlobeNewsWire
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call

Friday Mar 17 2023 at 09:00

GERMANTOWN, Md., March 17, 2023 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, March 21, 2023, to discuss the company’s corporate progress and other developments.


24/7 Wall Street
New Dimensions Trading Discloses Large Position in ORGS / Orgenesis

Wednesday Nov 23 2022 at 00:27

Fintel reports that New Dimensions Trading has filed a 13G form with the SEC disclosing ownership of 1,370,000 shares of Orgenesis Inc (ORGS).


Seeking Alpha
Orgenesis (ORGS) Q3 2022 Earnings Call Transcript

Sunday Nov 13 2022 at 21:29

Orgenesis (NASDAQ:ORGS ) Q3 2022 Earnings Conference Call November 11, 2022 8:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson – Benchmark Company Operator Good morning, ladies and gentlemen and welcome to the Orgenesis Third Quarter 2022 Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, Mr.


GlobeNewsWire
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call

Thursday Nov 10 2022 at 08:30

GERMANTOWN, Md., Nov. 10, 2022 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 8:00 AM Eastern Time on Friday, November 11, 2022 to discuss the company’s corporate progress and other developments.


Seeking Alpha
Orgenesis, Inc’s (ORGS) CEO Vered Caplan on Q2 2022 Results – Earnings Call Transcript

Tuesday Aug 16 2022 at 17:22

Orgenesis, Inc. (NASDAQ:ORGS ) Q2 2022 Earnings Conference Call August 16, 2022 11:00 AM ET Company Participants David Waldman – Investor Relations Vered Caplan – Chief Executive Officer Neil Reithinger – Chief Financial Officer Conference Call Participants Bruce Jackson – The Benchmark Company Operator Good day, ladies and gentlemen, and welcome to the Orgenesis Business Update Call. [Operator Instructions] It is now my pleasure to turn the floor over to your host, David Waldman from Investor Relations.


Proactive Investors
Orgenesis sees 2Q revenue of $7.2M; eyes future sales from POCare platform

Tuesday Aug 16 2022 at 11:59

Orgenesis (NASDAQ:ORGS) Inc announced second-quarter 2022 revenue of $7.2 million and provided a business update for the period ending June 30, 2022. The global biotech company also said it secured a $10 million loan from investment firm Metalmark Capital Partners for Orgenesis (NASDAQ:ORGS)’ point of care (POCare) services business for treating patients.


GlobeNewsWire
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call

Monday Aug 15 2022 at 09:14

GERMANTOWN, Md., Aug. 15, 2022 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it will host a conference call at 11:00 AM Eastern Time on Tuesday, August 16, 2022 to discuss the company’s corporate progress and other developments.


Proactive Investors
Orgenesis enters second phase of POCare Platform rollout; sees recurring revenues from long-term contracts for the next 2-3 years

Tuesday May 24 2022 at 08:09

Orgenesis (NASDAQ:ORGS) Inc, the global biotech company working to unlock the full potential of cell and gene therapies, has said it is entering the second phase of its POCare Platform rollout, and expects to benefit from recurring revenue streams from long-term contracts for the next two to three years. This follows the building of a robust network of POCare centers across Europe, Asia and the Middle East and the implementation of its POCare supply strategy in the US, the company said.


Proactive Investors
Orgenesis says consortium led by its MIDA Biotech subsidiary wins 4 million euro grant supporting cutting edge technology

Tuesday May 03 2022 at 07:52

Orgenesis (NASDAQ:ORGS) Inc said that a consortium led by its subsidiary, MIDA Biotech, has won a 4-million-euro grant under the European Innovation Council Pathfinder Challenge Program which supports cutting-edge science and technology in order to create new market opportunities. The consortium members include MIDA Biotech B.V.


Proactive Investors
Orgenesis inks agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8M

Thursday Mar 31 2022 at 10:22

Orgenesis (NASDAQ:ORGS) Inc said it has entered into a definitive securities purchase agreement with certain investors for a private placement for which it expects to receive gross proceeds of approximately $14.8 million before deducting related offering expenses. The company said the placement will see the sale of 4,933,333 shares of the company’s common stock at a purchase price of $3.00 per share and warrants to purchase up to 1,000,000 shares of common stock at an exercise price of $4.50 per share.


Seeking Alpha
Orgenesis’ (ORGS) CEO Vered Caplan on Q4 2021 Results – Earnings Call Transcript

Wednesday Mar 30 2022 at 22:50

Orgenesis’ (ORGS) CEO Vered Caplan on Q4 2021 Results – Earnings Call Transcript


Proactive Investors
Orgenesis sees revenue and profits soar in 2021 as its Point of Care platform gains traction around the globe

Wednesday Mar 30 2022 at 09:50

Orgenesis (NASDAQ:ORGS) Inc reported a more than four-fold increase in revenue in 2021 from a year earlier, thanks to growing uptake of its Point of Care (POCare) platform. For the 2021 financial year, Orgenesis (NASDAQ:ORGS) reported $35.5 million in revenue compared to $7.7 million in the previous year.


Proactive Investors
Orgenesis achieves latest milestone in its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Thursday Jan 27 2022 at 10:01

Orgenesis (NASDAQ:ORGS) Inc said it has achieved its latest milestone in the second phase of its collaboration with the Hospital Infantil Universitario Niño Jesús in Madrid, Spain. The milestone has been reached by completing the placement of an Orgenesis (NASDAQ:ORGS) Mobile Processing Unit and Lab (OMPUL) on site.


Proactive Investors
Wall Street stumbles amid looming interest rate hike worries

Tuesday Jan 18 2022 at 12:24

12:05pm: US markets trend downward US stocks continued to plummet midday on Tuesday, as investors eyed earnings reports from some major corporates and fretted over looming interest rate rises. At noon, the Dow Jones Industrial Average Index shed 1.4%, or 494 points, at 35,418, while both the broader S&P 500 and Nasdaq Composite continued to trade in the red, losing 1.4% and 1.8%, respectively.


Proactive Investors
Orgenesis and Johns Hopkins University to create Maryland center for cell therapy manufacturing

Tuesday Jan 18 2022 at 09:45

Orgenesis (NASDAQ:ORGS) Inc announced the next phase of collaboration with Johns Hopkins University, which involves the construction of a cell and gene therapy processing facility for point of care (POC) treatment of patients at Johns Hopkins. Construction work is planned to start in the second quarter of 2022 and the facility is expected to be operational in 2Q 2023.


Benzinga
Orgenesis-Theracell Joint Venture Secures €32M Grant From Greek Government

Monday Nov 29 2021 at 12:47

Orgenesis Inc (NASDAQ: ORGS) announced that its joint venture with Theracell Advanced Biotechnology S.A. in Greece has been designated a “Priority Investment of Strategic National Importance.


Proactive Investors
Orgenesis leading the charge at an exciting time for cell therapy

Monday Nov 29 2021 at 09:30

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platform consists of three core elements: POCare Therapeutics, POCare Technologies, and POCare Network What Orgenesis (NASDAQ:ORGS) does: OrGenesis (TSX:GDC) Inc. is focused on unlocking the potential of personalized therapies and closed processing systems through its cell and gene therapy platform. Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues.


Proactive Investors
Orgenesis and Theracell JV to receive up to €32M from Greek government to accelerate the rollout of therapies

Monday Nov 29 2021 at 09:28

Orgenesis (NASDAQ:ORGS) Inc announced that its joint venture (JV) with Theracell Advanced Biotechnology SA in Greece has been designated a “Priority Investment of Strategic National Importance.”   The global biotech company noted that the designation was awarded by Enterprise Greece, the official Greek national investment and trade promotion agency, which is responsible for the allocation of the government funds.


Proactive Investors
Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy center

Monday Nov 15 2021 at 08:57

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.


Seeking Alpha
Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results – Earnings Call Transcript

Saturday Nov 06 2021 at 16:42

Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results – Earnings Call Transcript


Proactive Investors
Orgenesis reports 425% surge in 3Q revenue as POCare platform gains scale

Thursday Nov 04 2021 at 09:11

Orgenesis (NASDAQ:ORGS) Inc announced a more than five-fold increase in third-quarter revenue as it continues to roll out its Point of Care (POCare) platform.  The global biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs), also reported a strong rise in revenue for the first nine months of its financial year to September 30, 2021, to $28.6 million, compared to just $5.3 million for the same period last year.


GlobeNewsWire
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

Tuesday Nov 02 2021 at 09:00

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Thursday, November 4, 2021 to discuss the Company’s corporate progress and other developments.


Proactive Investors
Orgenesis leading the charge at an exciting time for cell therapy

Tuesday Aug 31 2021 at 07:03

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platform consists of three core elements: POCare Therapeutics, POCare Technologies, and POCare Network What Orgenesis (NASDAQ:ORGS) does: OrGenesis (TSX:GDC) Inc. is focused on unlocking the potential of personalized therapies and closed processing systems through its cell and gene therapy platform. Cell and gene therapies (CGTs) use modified cells or cellular matter to treat, prevent or cure serious health issues.


Proactive Investors
Orgenesis strikes collaboration agreement with Savicell Diagnostics to advance its cell and gene therapy platform

Monday Aug 23 2021 at 08:57

Orgenesis Inc announced a new collaboration with biotech firm Savicell Diagnostics Ltd to accelerate the development and manufacturing of its cell and gene therapy platform. The wide-ranging agreement sees Orgenesis using Savicell’s immunometabolism platform to help advance its own platforms on a number of fronts.


GlobeNewsWire
Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Monday Aug 23 2021 at 08:00

Goal to accelerate development, QC testing and manufacturing  of Orgenesis’ cell and gene therapy platform


Proactive Investors
Orgenesis sees 2Q 2021 revenue jump by 500% year-over-year

Thursday Aug 05 2021 at 09:55

Orgenesis Inc said its 2Q 2021 revenues rose from $1.75 million to $10.5 million compared to the same period in 2020.  The international biotech company, which is focused on unlocking the full potential of cell and gene therapies (CGTs) in an affordable and accessible format, credited the Orgenesis Point of Care (POCare) Platform as a key factor to the profit boost.


GlobeNewsWire
Orgenesis Schedules Second Quarter 2021 Business Update Conference Call

Tuesday Aug 03 2021 at 08:30

GERMANTOWN, Md., Aug. 03, 2021 (GLOBE NEWSWIRE) — Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies, today announced that it plans to host a conference call at 8:30 AM Eastern Time on Thursday, August 5, 2021 to discuss the Company’s corporate progress and other developments.


Proactive Investors
Orgenesis says Ranpirnase advancing towards multiple indications after FDA consultation and presentation of positive results

Tuesday Jul 06 2021 at 08:46

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced multiple milestones in the development of Ranpirnase for multiple indications, including anogenital warts, adenoviral conjunctivitis and even coronavirus (COVID-19).  First, Orgenesis has completed its pre-Investigational New Drug (IND) consultation with the US Food and Drug Administration (FDA), discussing RanTop (Ranpirnase topical gel) for the treatment of anogenital warts (AGW).

crisis_alert
Orgenesis Bankruptcy Risk

The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.

Learn more at Investopediaopen_in_new

warning

Orgenesis’s Altman Z-score is -0.78 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.

Derived from SEC.GOV filing dataopen_in_new

account_balance
Orgenesis Insider Trading

Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.

Learn more at Investopediaopen_in_new

help

Over the last 3 months, there has been no insider trading in Orgenesis.

Derived from SEC.GOV filing dataopen_in_new

insights
Debt & Income Analysis

Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.

Learn more at WallStreetPrepopen_in_new

sentiment_very_satisfied

Orgenesis’s Income Quality of 2.36 is greater than its Industry Group of 0.71 (232.4% greater)

sentiment_very_satisfied

Orgenesis’s Income Quality of 2.36 is greater than its Major Industry Group of 0.73 (223.3% greater)

sentiment_very_satisfied

Orgenesis’s Income Quality of 2.36 is greater than its Sector of 0.77 (206.5% greater)

Derived from SEC.GOV filing dataopen_in_new


Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.

Learn more at Investopediaopen_in_new

warning

Orgenesis’s Current Ratio of 3.55 is lower than its Industry Group of 4.8 (-26.0% lower)

warning

Orgenesis’s Current Ratio of 3.55 is lower than its Major Industry Group of 4.34 (-18.2% lower)

sentiment_very_satisfied

Orgenesis’s Current Ratio of 3.55 is greater than its Sector of 2.61 (36.0% greater)

Derived from SEC.GOV filing dataopen_in_new

query_stats
Value Analysis

PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.

Learn more at Investopediaopen_in_new

help

Cannot compare a negative PE Ratio (-2.39 & -1.4)

help

Cannot compare a negative PE Ratio (-2.39 & -1.2)

help

Cannot compare a negative PE Ratio (-2.39 & -0.41)

Derived from SEC.GOV filing dataopen_in_new


The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.

Learn more at Investopediaopen_in_new

sentiment_very_satisfied

Orgenesis’s PB Ratio of 0.5 is lower than its Industry Group of 1.34 (-62.7% lower)

sentiment_very_satisfied

Orgenesis’s PB Ratio of 0.5 is lower than its Major Industry Group of 1.42 (-64.8% lower)

sentiment_very_satisfied

Orgenesis’s PB Ratio of 0.5 is lower than its Sector of 1.67 (-70.1% lower)

Derived from SEC.GOV filing dataopen_in_new

settings_suggest
Efficiency Analysis

ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.

Learn more at Investopediaopen_in_new

sentiment_very_satisfied

Orgenesis’s ROE of -0.21 is greater than its Industry Group of -0.45 (53.3% greater)

sentiment_very_satisfied

Orgenesis’s ROE of -0.21 is greater than its Major Industry Group of -0.39 (46.2% greater)

warning

Orgenesis’s ROE of -0.21 is lower than its Sector of -0.04 (-425.0% lower)

Derived from SEC.GOV filing dataopen_in_new


ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.

Learn more at Investopediaopen_in_new

sentiment_very_satisfied

Orgenesis’s ROCE of -0.1 is greater than its Industry Group of -0.43 (76.7% greater)

sentiment_very_satisfied

Orgenesis’s ROCE of -0.1 is greater than its Major Industry Group of -0.37 (73.0% greater)

warning

Orgenesis’s ROCE of -0.1 is lower than its Sector of -0.04 (-150.0% lower)

Derived from SEC.GOV filing dataopen_in_new

More Stocks